Key result
Phα1β produces only ~13% hERG potassium channel inhibition without affecting cell viability.
Why the study?
Regulatory agencies require evaluation of new drugs on human ERG potassium channels to assess potential cardiac safety risks.
Phα1β does not significantly inhibit the hERG potassium channel or affect cell viability, supporting its cardiac safety profile for further development as an analgesic.
Answers are grounded in this paper and cite their sources.
Supports Phα1β analgesic development; leaves open cardiac safety confirmation in humans.
Background: This study examines the impact of Phα1β, a spider peptide derived from the venom of Phoneutria nigriventer, on the Kv11.1 potassium channel in HEK293 cells transfected with the human ERG potassium channel. Phα1β inhibits high-voltage calcium channels and acts as an antagonist of the TRPA1 receptor, both of which play crucial roles in pain transduction pathways. Over the past 15 years, our research has demonstrated the potential of Phα1β, in both its native and recombinant forms, as a promising analgesic drug through preclinical tests conducted on rodent pain models. Regulatory agencies require the evaluation of new drugs on human ERG channels. Methods: To assess hERG potassium channel inhibition, we utilized the FLIPR® Potassium Assay, a commercially available kit. The assay involved testing the effects of Phα1β alongside the well-established hERG potassium channel blocker dofetilide, which served as a positive control. The viability of HEK-293 cells was assessed using the colorimetric MTT reduction test (3-(4, dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), whereby viable cells reduce the MTT salt, forming a formazan complex within their mitochondria, as previously described. Results: Phα1β was tested at concentrations of 56, 225, 450, and 900 pMol, resulting in a discreet inhibition of hERG potassium channel activity at higher concentrations, approximately 13.47%, with an IC50 value exceeding 900 pMol. Dofetilide, administered at concentrations ranging from 0.0001 to 10 µM, displayed a concentration-dependent inhibition of the hERG potassium channel, with a mean IC50 value of 0.1642 µM (0.1189-0.2282 µM). To evaluate cytotoxicity, HEK293-hERG cells were exposed to Phα1β concentrations of 56/900 pMol for 24 hours, resulting in no significant alteration in cell viability. Conclusion: Our findings indicate that even at high concentrations, Phα1β does not impede the functionality of the hERG potassium channel nor affect cell viability.
No takes yet. Share an insight, caveat, or question.
Calixto et al. (2025) studied this question. Phα1β vs. dofetilide was evaluated on hERG potassium channel inhibition (IC50 > 900 pMol). Phα1β at concentrations up to 900 pMol resulted in only 13.47% inhibition of hERG potassium channel activity (IC50 > 900 pMol) and did not affect cell viability.
Synapse has enriched 10 related papers. Consider them for comparative context: